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Various properties have been evaluated for the binding to tissue culture substrata of proteolytic fragments of human 
plasma or cellular fibronectins containing complementary sequences from the individual and alternatively spliced chains, 
since related fragments are known to yield differing adhesive responses from cells. These studies utilize ELISA methods 
and a polyclonal antiserum directed to human pFN for direct measurement or an occupancy test utilizing anti-albumin. 
Very related fragments (with or without an extra type III homology unit or extra domain. orb) have significantly different 
properties in substratum binding and such differences provide a partial explanation for alteration of cellular adhesive 
responses on such fragments. 
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evaluated in this study by ELISA [18] of the com- 
plementary FN fragments binding to several 
substrata using a polyclonal antiserum raised to 
human pFNs [19]. ELISA methods have also 
described the binding of albumin and y-globulins 
to various biomaterial surfaces [20]. 
2. MATERIALS AND METHODS 
2. I. Fibronectin fragments 
pFN from human plasma and cFN from cells were purified by 
gelatin-Sepharose affinity chromatography [ 10,151. Fragments 
from thermolysin digests were purified by affinity 
chromatography on columns of gelatin-, heparin-, and/or 
monoclonal antibody-Sepharose [15]. cFN from normal or 
transformed cells generated fragments enriched in ED, or EDb, 
respectively [3]. The following family of fragments are obtained 
from adjacent sequences with minimal oss of amino acids at the 
cleavage point (see fig.1 from [lo]). From the a-chain of pFN, 
F145 (145 kDa) contains an RGDS-dependent cell-binding do- 
main (Cell& the C-terminal heparin-binding domain (Hepn), 
and five amino acids of IIICS. Cleavage of F145 generates FllO 
containing Cellr but not Hepn; the complementary F29 from 
F145 cleavage contains Heptr and five amino acids of IIICS at 
its C-terminus. Comparable fragments from the&chain of pFN 
are F155 with both Cellr and Hepn domains, containing an addi- 
tional type III homology unit but no IIICS sequence. Fragments 
from F155 are FllO with Cell, (identical to F145-derived FllO) 
and F38 with Hepn, as well as the additional type III homology 
unit. From normal cell FN, a mixture of 44 kDa and 47 kDa 
fragments was obtained retaining Hepn, ED,, and five amino 
acids of IIISC at the C-terminus. F120 was derived from cFN of 
transformed cells and contains all the sequence of FllO plus 
EDb; this fragment is cleaved into F35 containing Cell1 and F90 
containing EDb. 
2.2. Protein adsorption 
Tissue culture cluster dishes (%-well; Costar, Cambridge, 
MA) were rinsed once with phosphate-buffered saline (PBS) and 
adsorbed for 1 h (or as indicated) at 37°C with the indicated 
proteins at varying concentrations diluted in serum-free 
medium. Wells were rinsed three times with PBS and post- 
adsorbed with attachment medium (250,~g/ml of heat inac- 
tivated BSA or myoglobin [see below] in medium) for 1 h at 
37°C. 
2.3. Enzyme-linked immunosorbent assay fl8j 
Goat antiserum to human pFN has been described [19] and 
does not react with BSA (see below) used to block available sub- 
stratum sites. Rabbit antisera to BSA were used for comparison 
(gift of Dr Abram Stavitsky of this Department). Sera are 
diluted in 1% (w/v) BSA (for anti-pFN) or myoglobin (for anti- 
BSA) in PBS and added to wells treated with test proteins. Wells 
were incubated for 1 h at 37’C, rinsed three times with 0.1% 
BSA or myoglobin (w/v) in PBS, and incubated for 1 h at 37°C 
with an alkaline phosphatase conjugate of rabbit anti-goat IgG 
(Zymed Laboratories, San Francisco, CA) [or, in some cases, 
goat anti-rabbit IgG conjugate to evaluate anti-BSA reactivity]; 
wells were rinsed three times again. Enzyme substrate @-nitro- 
36 
phenyl phosphate; Sigma Chemical Co.) in 50 mM glycine buf- 
fer, pH 9.6, with 1 mM MgCls was diluted to 1 mg/ml and add- 
ed at lOO~l/well. A405 “,,, values on a Perkin-Elmer ELISA 
reader were used within the linear range and routinely gave 
standard errors in multiple determinations of between + 2 and 
8%. 
3. RESULTS AND DISCUSSION 
Antisera were tested with the ELISA method 
against pFN- or BSA-coated substrata at varying 
dilutions as shown in fig.1 to determine antibody- 
excess conditions of reactivity; as demonstrated 
previously [ 12,131, the 20 pg/ml of pFN or BSA 
used to coat wells saturates the substratum. Anti- 
pFN reacted effectively with pFN but not BSA sub- 
strata (fig. 1A) and a dilution of 1O-2.5 was chosen 
for the experiments. Anti-BSA demonstrated 
specificity for the BSA substratum above dilutions 
of 10e3 and this dilution was chosen as the 
antibody-excess condition. 
Reactivity of pFN or cFN fragments were then 
tested at this anti-pFN dilution for comparison 
with intact pFN (fig.2). Fragments may contain on- 
ly some of the epitopes represented in the whole 
molecule, yielding less saturable reactivity in the 
ELISA; they may also contain unique epitopes 
masked by folding of intact FN. a-chain fragments 
of pFN give differing saturation reactivities when 
the concentration of the adsorbing fragment is 
varied (fig.2A). F145 yields reactivity almost in- 
distinguishable from pFN, even though it 
represents only 60-65% of the sequence of the en- 
tire molecule. This also indicates that on a weight 
basis F145 (containing both Cellr and Hepn do- 
mains) binds to the substratum as effectively as the 
intact molecule. Interestingly, Fl 10 (containing the 
Cellr domain) derived from F145 does not saturate 
the substratum below an adsorbing concentration 
of 50rg/ml while the complementary Hepn- 
containing fragment F29 appears to be saturable 
(to be tested below) at 20-50pg/ml but yields a 
much lower reactivity with the antiserum, sug- 
gesting that most of the epitopes in F145 in this 
goat antiserum are localized in sequences found in 
Fl 10 or that much higher concentrations of F29 are 
required to drive the substratum binding to com- 
pletion. When the P-chain fragments of pFN are 
tested (fig.2B), similarities and differences in 
ELISA reactivity are noted; F155 containing both 
domains binds as effectively as F145, while the 
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Fig. 1. ELISA reactivity of pFN or BSA substrata s a function 
of antisera dilution. Anti-pFN (A) or anti-BSA (B) were diluted 
with PBS as indicated (antibody dilution) and tested for reactivi- 
ty in wells coated with 20 Fg/ml pFN or 250 ,cg/ml BSA with the 
ELISA method (A405 ,,,,, at 30 min). 
Hepn-containing F38 saturates the substratum at 
approx. 20 pg/ml and yields better reactivity with 
the antiserum than F29 (in fig.2A). 
Cellular FN fragments were then tested for com- 
parison with the pFN-derived fragments (note that 
the antiserum was raised to human pFN). As 
shown in fig.2C, F120 from transformed cFN and 
comparable to FllO from pFN (with the addition 
of the alternatively spliced ED, sequence) binds to 
the substratum with a dose dependence in- 
distinguishable from that of FllO. However, 
cleavage of F120 yields F90 which contains none of 
the well-characterized binding domains but which 
reacts almost as effectively in the ELISA while the 
complementary F35 containing the Cellr domain 
yields the lowest reactivity in the ELISA (fig.2C). 
Fragments 44 + 47 from normal cFN containing 
the Hepn domain and the Ed, sequence bind in a 
similar manner to F38 (fig.2C), demonstrating that 
the ED, sequences do not affect binding and anti- 
body reactivity as much as the extra type III 
homology unit found in F38 and F44 + 47 but not 
in F29. Therefore, the larger fragments appear to 
bind more effectively than the smaller fragments 
with the caveat that small fragments with related 
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Fig.2. Concentration dependence of ELISA reactivity with anti- 
pFN of pFN, pFN a-chain fragments (A), pFN b-chain 
fragments (B), or cFN fragments (C). The origin of each class of 
fragments is displayed at the right of the appropriate panel. All 
data were obtained from the same experiment for direct com- 
parison. 
sequences can have very different binding proper- 
ties (e.g., F38 or F44 + 47 compared to F29 or 
F35). 
Another approach for testing whether fragments 
saturate the substratum utilizes bovine serum 
albumin to bind to available sites, after prior ad- 
sorption of FN fragments, and then testing reac- 
tivity of the substratum to anti-BSA by ELISA, 
i.e., testing substratum occupancy by the FN 
fragments and their ability to block BSA binding. 
As shown in fig.3A for pFN a-chain fragments, 
F145 blocks subsequent albumin binding at con- 
centrations >50 pg/ml (identical to pFN; not 
shown). In contrast, FllO adsorption blocks the 
substratum from BSA occupancy to 10 pg/ml and 
then occupancy becomes poorer at higher FllO 
concentrations as if FllO is facilitating BSA bind- 
37 
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Fig.3. FN fragment occupancy on substratum as determined by 
BSA post-adsorption and anti-BSA ELISA. Fragments from 
pFN m-chain (A), pFN &chain (B), cFN (C), or 250 pg/ml BSA 
alone as a control (A,B,C) were adsorbed to wells at increasing 
concentrations and rinsed out of wells, which were then post- 
adsorbed with BSA. ELISA reactivity with anti-BSA was then 
tested. All data were obtained from the same experiment for 
direct comparison. 
ing or is being labilized off the substratum. F29 oc- 
cupancy was poor at all concentrations, consistent 
with the anti-pFN ELISA data of fig.2A. For pFN 
P-fragments (fig.3,B), FlS5 occupancy was very 
good while F38 occupancy increased to lOpg/ml 
and then facilitated BSA replacement at higher 
concentrations. For cFN fragments (fig.3C), 
F44 + 47 occupied the substratum more effectively 
than pFN-derived F29 or F38 while both F120 and 
its derivatives (F90 and F35) gave biphasic plots. 
Therefore, larger fragments occupy the substratum 
more effectively than the smaller fragments which 
display complex relationships with subsequent 
BSA binding. 
Polylysine coatings on surfaces facilitate adhe- 
sion responses of some cell types. Therefore, the 
binding of pFN and fragments was evaluated in 
plastic wells or in wells precoated with polylysine 
(20pg/ml for 1 h) using anti-pFN in the ELISA 
(fig.4). In most cases, the amounts bound were in- 
distinguishable on the two substrata, demonstrat- 
ing that adhesion differences cannot be due to 
quantitative differences in FN products bound; 
however, their conformation could be quite dif- 
ferent, although not detected here by antibody 
binding. Two exceptions were noted. Both F15.5 
from the&chain and F145 from the a-chain bound 
comparably to plastic while the latter bound less 
well on polylysine (by Student’s t-test, p < 0.02), in- 
dicating that the extra type III homology unit in 
F155 confers greater interaction with a positively 
charged matrix. 
Two different experiments were designed to test 
the kinetics and stability of binding of fragments to 
plastic wells. First, the time of adsorption of 
fragments to wells was varied prior to washing ex- 
cess fragment out of wells for testing immediately 
with anti-pFN by ELISA (not shown). For pFN, 
F155, F145, and F29, binding was immediate and 
maximal. However, for FllO, F90, and to some ex- 
tent F44 + 47, binding increased during the initial 
20 min, suggesting cooperative interaction in the 
binding of these fragments to substrata. Second, 
the stability of binding was evaluated over a 24 h 
period (fig.5). pFN-derived fragments (fig.SA) ap- 
peared quite stable, with the exception of F38 
FN fragments 
Fig.4. Adsorption of fragments to polylysine-coated substrata. 
Wells were left untreated (plastic) or coated with 20 /cg/ml poly- 
L-lysine (polylysine) for 1 h, rinsed, then adsorbed with 
50yg/ml of the indicated fragments or pFN for 1 h, rinsed, 
post-adsorbed with BSA, and finally rinsed with PBS. ELISA 
reactivity was tested with anti-pFN. 
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Fig.5. Stability of fragment binding to substrata. Plastic wells 
were coated with the indicated fragments, pFN, or BSA and 
then rinsed with PBS. Adhesion medium (250pg/ml BSA in 
DMEM) was added to wells for varying periods of time and 
ELISA reactivity tested with anti-pFN. All data were obtained 
from the same experiment for direct comparison. 
which decreased slightly during the initial several 
hours. cFN fragments (fig.SB) F120 and F90 were 
stable initially but then lost reactivity on the sub- 
stratum during the subsequent 20 h. These results 
show that there is no massive loss of fragment from 
substrata in the absence of attaching cells in adhe- 
sion medium but that some of the fragments are 
more labile than others. 
In summary, ELISA methods were used to 
demonstrate differing amounts and/or conforma- 
tion of related FN fragments on artificial sub- 
strata. An additional type III homology unit or 
alternatively spliced sequence in FN chains can 
have significant effects on substratum-binding 
properties and, ultimately, on the adhesive 
responses of cells as mediated by binding domains 
represented in these various fragments. 
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